Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline

Co-Diagnostics, Inc.

2025-Q1 EPS reported -$0.24 revenue$50,277

Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.
Net loss of $7.5M ($0.24 loss per share) compared to net loss of $9.3M ($0.31 per share) in Q1 2024.
Operating loss improved to $8.6M from $10.3M YoY; operating expenses decreased 18.2%.
Cash and marketable securities totaled $21.5M as of March 31, 2025.
On track to begin clinical evaluations for 4 tests and complete India manufacturing facility by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.